SOPHiA GENETICS Reports Q3 2026 Revenue Growth of 25% Driven by U.S. Expansion
SOPHiA GENETICS SA reported strong third-quarter 2026 results, with revenue reaching $24.3 million, a 25% increase year-over-year. The growth was primarily fueled by significant expansion in the United States market, which saw 41% revenue growth as hospitals increasingly adopt in-house testing via the company's platform. Additionally, liquid biopsy volumes surged by over 100% compared to the previous year. The company demonstrated improved operational efficiency, narrowing its adjusted EBITDA loss to $6.1 million from $8.8 million in the prior year period. While facing foreign exchange headwinds and ongoing litigation related to Guardant Health, management reaffirmed full-year revenue guidance at the upper end of $94 million to $96 million. With a cash position of $94 million, the company maintains its focus on reaching long-term profitability through AI-driven efficiencies.
Topics: EBITDA Improvement Financial Guidance Genomics Revenue Growth